调脂药物对高脂模型大鼠炎性因子的影响  

Effects of lipid-lowering drugs on inflammation factors in hyperlipidemia rats

作　　者：高丽君[1] 齐晓勇[2] 王秀平[2] 魏欣[2] 沈春梅[2] 

机构地区：[1]河北医科大学内科教研室,河北石家庄050051 [2]河北省人民医院心内科

出　　处：《中国老年学杂志》2008年第21期2083-2085,共3页Chinese Journal of Gerontology

基　　金：河北省科学技术研究与发展计划项目(08276101D-102)

摘　　要：目的探讨调脂药物瑞舒伐他汀和非诺贝特对高脂模型大鼠治疗前后炎性因子水平及动脉粥样硬化(AS)的影响。方法40只雄性Wistar大鼠随机分为4组,正常对照组10只、高脂模型对照组10只、瑞舒伐他汀药物干预组10只和非诺贝特药物干预组10只,正常对照组给予正常饮食,高脂模型对照组和药物干预组给予高脂饮食,8w末高脂模型建立,第9周开始高脂模型对照组和药物干预组分别给予生理盐水、瑞舒伐他汀、非诺贝特灌胃,第18周末处死大鼠,检测血脂及高敏-C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白介素-6(IL-6)、白介素-8(IL-8)的水平,并观察主动脉血管内皮病理形态学的变化。结果第8周成功建立高脂模型,第18周与高脂模型对照组比较,瑞舒伐他汀干预组总胆固醇(TC)、低密度脂蛋白(LDL)、hs-CRP、TNF-α、IL-8的水平明显降低(P<0.05),非诺贝特组干预后可中度降低甘油三酯(TG),明显降低hs-CRP的水平(P<0.05)。病理形态学变化:瑞舒伐他汀药物干预组与高脂模型对照组比较内膜增生不明显,泡沫细胞减少。结论瑞舒伐他汀对AS有抑制作用,在降低血脂的同时,可能与抑制炎症有关。非诺贝特组可降低TG,有轻度抗炎作用。Objective To study the effects of lipid-lowering drugs rosuvastatin and fenofibrate on inflammation factors and atherosclerosis （AS） in hyperlipidemia rats model. Methods Forty male Wistar rats were randomly divided into control （normal diet）, model, rosuvastatin and fenofibrate （high lipid diet） groups, 10 rats in each group. By the end of the 8th week, hyperlipoidemia models were established. From the 9th week, model, rosuvastatin and fenofibrate groups were intragastrically treated with physiological saline, rosuvastatin and fenofibrate respectively. The rats were killed by the end of the 18th week. The levels of blood lipid, high sensitive CRP （hs-CRP）, tumor necrosis factor （TNF）-α, interleukin （IL）-6 and IL-8 were measured respectively. Pathological examination was performed on endothelium of the artery. Results By the end of the 8th week, hyperlipoidemia models were successfully established. At the end of the experiment, rosuvastatin group had decreased total cholesterol （TC）, low-density lipoprotein （LDL）, hs-CRP, TNF-β and IL-8 than model group （P 〈 0. 05 ）, Fenofibrate group had reduced triglyceride （TG） and hs-CRP （P 〈 0. 05 ）. There was no significant difference in artery endothelium hyperplasia between rosuvastatin group and model group, while＇the foam cells were reduced in rosuvastatin group. Conclusions Rosuvastatin could play inhibitive role in AS and reduce the level of lipids, which might be related to inhibiting inflammation. Fenofibrate could reduce TG level and play mild anti-inflammation role.

关 键 词：高脂血症 炎性因子 瑞舒伐他汀 非诺贝特 

分 类 号：R972.6[医药卫生—药品]